| Literature DB >> 20025047 |
Gregg D Cappon1, Graham P Bailey, Jochen Buschmann, Maureen H Feuston, J Edward Fisher, Kok Wah Hew, Alan M Hoberman, Yojiro Ooshima, Donald G Stump, Mark E Hurtt.
Abstract
The objective of juvenile animal toxicity studies of pharmaceuticals is to obtain safety data, including information on the potential for adverse effects on postnatal growth and development. Studies in juvenile animals may assist in identifying postnatal developmental toxicities or other adverse effects that are not adequately assessed in the routine toxicity evaluations and that cannot be safely or adequately measured in pediatric clinical trials. Unlike the traditional reproductive and developmental toxicology studies that have been discussed in the accompanying reports, the design requirements for toxicity studies in juvenile animals are not explicitly defined in regulatory guidance. However, studies in juvenile animals can be useful in providing safety information necessary to enable pediatric clinical trials in pediatric patients or when there are special concerns for toxicities that cannot be safely or adequately measured in clinical trials. These juvenile animal toxicity studies are designed on a case-by-case basis. General design considerations and examples of study designs for assessment of juvenile animal toxicity are discussed. 2009 Wiley-Liss, Inc.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20025047 DOI: 10.1002/bdrb.20220
Source DB: PubMed Journal: Birth Defects Res B Dev Reprod Toxicol ISSN: 1542-9733